(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
Live Chart Being Loaded With Signals
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials...
Stats | |
---|---|
本日の出来高 | 1.94M |
平均出来高 | 4.37M |
時価総額 | 16.28B |
EPS | HKD0.240 ( Q4 | 2023-12-31 ) |
Last Dividend | HKD0.140 ( 2023-06-09 ) |
Next Dividend | HKD0 ( N/A ) |
P/E |
8.61 (Sector) 14.27 (Industry) 0 |
ATR14 | HKD0.00300 (0.06%) |
ボリューム 相関
China Grand 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
China Grand 相関 - 通貨/商品
China Grand 財務諸表
Annual | 2023 |
収益: | HKD10.53B |
総利益: | HKD6.52B (61.96 %) |
EPS: | HKD0.540 |
FY | 2023 |
収益: | HKD10.53B |
総利益: | HKD6.52B (61.96 %) |
EPS: | HKD0.540 |
FY | 2022 |
収益: | HKD9.56B |
総利益: | HKD5.95B (62.24 %) |
EPS: | HKD0.590 |
FY | 2021 |
収益: | HKD8.60B |
総利益: | HKD5.25B (61.03 %) |
EPS: | HKD0.677 |
Financial Reports:
No articles found.
China Grand Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.140 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0860 | 2019-06-12 |
Last Dividend | HKD0.140 | 2023-06-09 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | HKD0.542 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.54 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.64 | |
Div. Directional Score | 9.96 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
09 Jun 2023 | HKD0.140 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
06 Jun 2022 | HKD0.110 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
08 Jun 2021 | HKD0.110 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
26 Jun 2020 | HKD0.0960 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
12 Jun 2019 | HKD0.0860 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2030.HK | Ex Dividend Junior | 2023-08-17 | Annually | 0 | 0.00% | |
0467.HK | Ex Dividend Junior | 2023-07-18 | Annually | 0 | 0.00% | |
1600.HK | Ex Dividend Knight | 2023-10-24 | Semi-Annually | 0 | 0.00% | |
0086.HK | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
6699.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
1112.HK | Ex Dividend Junior | 2023-09-04 | Annually | 0 | 0.00% | |
2343.HK | Ex Dividend Knight | 2023-08-11 | Annually | 0 | 0.00% | |
0697.HK | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1846.HK | Ex Dividend Knight | 2023-09-11 | Annually | 0 | 0.00% | |
0267.HK | Ex Dividend Junior | 2023-09-22 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.179 | 1.500 | 6.43 | 9.64 | [0 - 0.5] |
returnOnAssetsTTM | 0.0835 | 1.200 | 7.22 | 8.66 | [0 - 0.3] |
returnOnEquityTTM | 0.127 | 1.500 | 9.70 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.264 | -1.000 | 7.36 | -7.36 | [0 - 1] |
currentRatioTTM | 1.224 | 0.800 | 8.88 | 7.10 | [1 - 3] |
quickRatioTTM | 0.843 | 0.800 | 9.75 | 7.80 | [0.8 - 2.5] |
cashRatioTTM | 0.239 | 1.500 | 9.78 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.148 | -1.500 | 7.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 12.98 | 1.000 | 6.30 | 6.30 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.636 | 2.00 | 9.79 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.494 | 2.00 | 9.75 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.221 | -1.500 | 9.12 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.620 | 1.000 | 3.01 | 3.01 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.253 | 1.000 | 6.94 | 6.94 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.667 | 1.000 | 7.41 | 7.41 | [0.2 - 2] |
assetTurnoverTTM | 0.468 | 0.800 | -0.216 | -0.172 | [0.5 - 2] |
Total Score | 12.28 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.72 | 1.000 | 9.22 | 0 | [1 - 100] |
returnOnEquityTTM | 0.127 | 2.50 | 9.81 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.494 | 2.00 | 9.84 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 5.56 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.636 | 2.00 | 9.79 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.264 | 1.500 | 7.36 | -7.36 | [0 - 1] |
pegRatioTTM | 0.657 | 1.500 | 8.95 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.212 | 1.000 | 7.21 | 0 | [0.1 - 0.5] |
Total Score | 7.64 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
China Grand
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers pharmaceutical preparations, including cerebro-cardiovascular emergency medicines; respiratory, ophthalmic, anti-infection, and ENT medicines; oncology medicines; and rare disease medicines. It also provides medical devices, such as vascular interventional medical devices comprising paclitaxel releasing coronary balloon dilatation catheters and paclitaxel releasing hemodialysis shunt balloon dilatation catheters; and ophthalmology related devices. In addition, the company offers biotechnology and health products, such as Taurine, amino acid products, steroid products, and bio-pesticides and agricultural antibiotics; and specialized pharmaceutical raw materials and other products, including metronidazole, chloramphenicol, epinephrine, dimethyl sulfate, nitromethane, etc. Further, the company offers agrochemicals, fine chemicals, and chemical medicines; ophthalmic gel and eye drops; steroid hormones active pharmaceutical ingredients and related intermediates; bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. Grand Pharmaceutical Group Limited has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited and changed its name to Grand Pharmaceutical Group Limited in November 2021. Grand Pharmaceutical Group Limited was incorporated in 1995 and is based in Central, Hong Kong.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。